New pill for Hard-to-Treat cancers shows early promise in small study
NCT ID NCT06625515
First seen Jan 11, 2026 · Last updated Jun 18, 2026 · Updated 30 times
Summary
This early-stage study tested a new oral drug, ATX-559, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Stephenson Cancer Center at OU Medicine
Oklahoma City, Oklahoma, 73104, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Colorado Cancer Center - Anschutz Medical Campus,
Aurora, Colorado, 80045, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.